A detailed history of Simplex Trading, LLC transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Simplex Trading, LLC holds 2,638 shares of STOK stock, worth $36,720. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,638
Previous 4,727 44.19%
Holding current value
$36,720
Previous $63,000 49.21%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$12.24 - $15.92 $25,569 - $33,256
-2,089 Reduced 44.19%
2,638 $32,000
Q2 2024

Jul 25, 2024

BUY
$11.03 - $17.52 $39,388 - $62,563
3,571 Added 308.91%
4,727 $63,000
Q1 2024

Apr 25, 2024

SELL
$4.12 - $14.17 $28,110 - $96,681
-6,823 Reduced 85.51%
1,156 $15,000
Q4 2023

Feb 02, 2024

BUY
$3.37 - $5.4 $17,854 - $28,609
5,298 Added 197.61%
7,979 $41,000
Q3 2023

Nov 01, 2023

SELL
$3.78 - $11.99 $180,963 - $574,009
-47,874 Reduced 94.7%
2,681 $10,000
Q2 2023

Aug 04, 2023

BUY
$7.93 - $13.82 $400,901 - $698,670
50,555 New
50,555 $537,000
Q4 2022

Feb 02, 2023

BUY
$7.07 - $15.69 $75,352 - $167,224
10,658 New
10,658 $98,000
Q2 2021

Aug 12, 2021

SELL
$30.53 - $41.09 $13,402 - $18,038
-439 Reduced 66.41%
222 $7,000
Q1 2021

Apr 26, 2021

BUY
$36.08 - $69.81 $23,848 - $46,144
661 New
661 $25,000
Q4 2020

Feb 02, 2021

SELL
$33.62 - $61.93 $40,411 - $74,439
-1,202 Closed
0 $0
Q3 2020

Oct 14, 2020

BUY
$22.23 - $37.48 $16,272 - $27,435
732 Added 155.74%
1,202 $40,000
Q2 2020

Jul 13, 2020

BUY
$20.26 - $29.73 $1,965 - $2,883
97 Added 26.01%
470 $11,000
Q1 2020

Apr 29, 2020

BUY
$16.8 - $34.15 $6,266 - $12,737
373 New
373 $8,000

Others Institutions Holding STOK

About Stoke Therapeutics, Inc.


  • Ticker STOK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,419,300
  • Market Cap $549M
  • Description
  • Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...
More about STOK
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.